Form 4: IRMD CEO Roger Susi Executes Planned Stock Sale

IRADIMED Corporation CEO Roger E. Susi sold 7,500 shares of common stock via a pre-arranged Rule 10b5-1 trading plan.

Summary

• CEO, President, and Chairman Roger E. Susi sold a total of 7,500 shares of IRADIMED Corporation (IRMD) common stock.
• The transactions occurred on May 26 and May 27, 2026.
• All sales were executed through the Phillip Susi 2008 Dynasty Trust.
• The sales were conducted under a Rule 10b5-1 trading plan adopted on November 5, 2025.
• Following these transactions, the reporting person maintains beneficial ownership of 2,165,000 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; the sale is clearly identified as part of a pre-planned 10b5-1 program, which is a routine administrative action for executives.

Positives

• The sales were executed pursuant to a pre-established Rule 10b5-1 trading plan, indicating the transactions were scheduled in advance rather than based on non-public information.

Negatives

• Insider selling by a CEO and major shareholder can sometimes be perceived negatively by the market as a signal of reduced confidence or profit-taking.

Risks

• Continued insider selling could potentially exert downward pressure on the stock price if perceived as a lack of long-term confidence by leadership.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing, as it is a standard disclosure of insider transaction activity.

Management Comments

• The reporting person has committed to providing full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard corporate governance practice for executives to diversify holdings without triggering market concerns regarding material non-public information.

Comparison to Industry Standards

• The use of a Rule 10b5-1 plan is the industry standard for executives to conduct orderly divestments while maintaining compliance with SEC regulations.

Related Party Transactions

• Transactions were conducted through the Phillip Susi 2008 Dynasty Trust, an entity associated with the reporting person.

Stakeholder Impact

• Minimal impact expected as the sales were pre-planned and represent a small fraction of the reporting person's total holdings.

Next Steps

• Continued monitoring of future Form 4 filings to track any further divestment activity by the CEO.

Key Dates

Keywords

IRMD, IRADIMED, Insider Trading, Form 4, Roger Susi, Stock Sale, Rule 10b5-1